These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 12393418

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
    Pan L, Delmonte J, Jalonen CK, Ferrara JL.
    Blood; 1995 Dec 15; 86(12):4422-9. PubMed ID: 8541530
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
    Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS, Cooke KR, Ferrara JL.
    Blood; 1999 Jun 15; 93(12):4071-8. PubMed ID: 10361103
    [Abstract] [Full Text] [Related]

  • 4. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice.
    O'Keeffe M, Hochrein H, Vremec D, Pooley J, Evans R, Woulfe S, Shortman K.
    Blood; 2002 Mar 15; 99(6):2122-30. PubMed ID: 11877288
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J, Zhao XY, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2005 Sep 14; 85(35):2497-502. PubMed ID: 16321278
    [Abstract] [Full Text] [Related]

  • 7. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
    Pan L, Bressler S, Cooke KR, Krenger W, Karandikar M, Ferrara JL.
    Biol Blood Marrow Transplant; 1996 Oct 14; 2(3):126-33. PubMed ID: 9199755
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient.
    Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, Ferrara JL.
    Transplantation; 2000 Feb 27; 69(4):691-3. PubMed ID: 10708136
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells.
    MacDonald KP, Rowe V, Clouston AD, Welply JK, Kuns RD, Ferrara JL, Thomas R, Hill GR.
    J Immunol; 2005 Feb 15; 174(4):1841-50. PubMed ID: 15699110
    [Abstract] [Full Text] [Related]

  • 14. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs.
    Morris ES, MacDonald KP, Rowe V, Banovic T, Kuns RD, Don AL, Bofinger HM, Burman AC, Olver SD, Kienzle N, Porcelli SA, Pellicci DG, Godfrey DI, Smyth MJ, Hill GR.
    J Clin Invest; 2005 Nov 15; 115(11):3093-103. PubMed ID: 16224535
    [Abstract] [Full Text] [Related]

  • 15. Impact of donor hematopoietic cells mobilized with G-CSF and plerixafor on murine acute graft-versus-host-disease.
    Arbez J, Saas P, Lamarthée B, Malard F, Couturier M, Mohty M, Gaugler B.
    Cytotherapy; 2015 Jul 15; 17(7):948-55. PubMed ID: 25813681
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
    Ji SQ, Chen HR, Wang HX, Yan HM, Pan SP, Xun CQ.
    Biol Blood Marrow Transplant; 2002 Jul 15; 8(5):261-7. PubMed ID: 12064363
    [Abstract] [Full Text] [Related]

  • 20. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.
    Drobyski WR, Majewski D.
    Blood; 1996 Jun 15; 87(12):5355-69. PubMed ID: 8652851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.